Skip Navigation

NIH: National Institutes of Health
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Keep Your Body Healthy
Go to the Home pageGo to the About Nida pageGo to the News & Events pageGo to the Funding pageGo to the Publications page
PhysiciansResearchersParents/TeachersStudents/Young AdultsEn Español Drugs of Abuse & Related Topics

NIDA Home > About NIDA > Organization > DBNBR   

Division of Basic Neuroscience and Behavioral Research (DBNBR)
gray line



Genetics and Molecular Neurobiology Research Branch

- Mission
- Program Areas
- Program Announcements
- Contacts
- Recent Initiatives


Mission

The GMNRB supports research on the genetic basis of addiction vulnerability, the fundamental cellular mechanisms that underlie addiction and the response to drugs of abuse, and basic neurobiology.


Program Areas

Development of neural pathways and brain structures that mediate drug abuse and addiction. This includes research on stem cell and progenitor cell induction, pattern formation, proliferation, and phenotypic restriction, specification of neuronal and glial cell fate, programmed cell death, guidance of glial and neuronal migration, and regulation of dendritic and axonal outgrowth, navigation, target selection, and synapse formation.

The role that transcription factors, scaffolding proteins, adhesion molecules, signaling molecules, cytoskeletal proteins, and other molecules play in mediating memory and learning and the neural adaptation to drugs of abuse.

Cell biology studies of addiction, including research on membrane and protein trafficking, signal transduction pathways, cytoskeletal rearrangements, protein-protein interactions, protein complex formation, synaptic vesicle formation, and ion movements.

Genetic studies of vulnerability to addiction, including animal and human molecular genetics studies, QTL-based research, and pharmacogenetics.

Molecular genetics and genomics studies related to underlying biology of the response to drugs of abuse, including model organism genomics, functional genomics, proteomics, gene expression studies, and mutagenesis studies.


Program Announcements

RFA-MH-09-030: Probes and Instrumentation for Monitoring and Manipulating Nervous System Plasticity (R01) Letters of Intent Receipt Date(s): August 16, 2008; Application Submission/Receipt Date(s): September 16, 2008

PAR-08-139: Enhancing Zebrafish Research with Research Tools and Techniques (R01)

PAR-08-035: Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Probe Production Centers Network (MLPCN) (R03)

PAR-08-034: Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Probe Production Centers Network (MLPCN) (X01)

PA-08-013: ELSI Small Research Grant Program (R03)

PA-08-012: ELSI Regular Research Program (R01)

PA-07-266: Networks and Pathways Collaborative Research Projects (R01)

PA-07-121: The Development of Frontal Cortex and Limbic System and Their Roles in Drug Abuse or Mental Health (R01)

NOT-DA-07-019: Notice of Availability of NIDA Genetics Consortium (NGC) Samples for Access by Qualified Investigators through NIDA Center for Genetic Studies

NOT-NS-07-009: Announcement for the US-JAPAN Brain Research Cooperative Program - US Component

PA-07-073: Molecular Genetics of Drug Addiction and Related Co-morbidities (R01)

PA-06-522: Networks and Pathways Collaborative Research Projects (R01)

PA-06-445: The Development of Frontal Cortex and Limbic System and Their Roles in Drug Abuse or Mental Health (R21)

PA-06-444: The Development of Frontal Cortex and Limbic System and Their Roles in Drug Abuse or Mental Health (R01)

NOT-DA-06-033: Notice of Intent to Publish a Program Announcement Encouraging Research in the Functional Genetics and Genomics of Drug Addiction


Contacts

Division Contact Information

Jonathan Pollock, Ph.D.
Branch Chief
(301) 435-1309

Dr. Pollock manages and oversees all activities of the GMNRB. Dr. Pollock continues to advocate for genetics, proteomics and developmental biology research at NIDA and has promoted collaboration between NIDA and the Office of National Drug Control Policy. Dr. Pollock has been actively involved in trans NIH initiatives such as the Brain Molecular Anatomy Project (B-MAP) and GenSAT. He has also taken a leadership role at the NIH in promoting the sharing of mouse resources generated with NIH funds.

Activities: NIH Mammalian Gene Collection Committee; Trans-NIH mouse and genomics resource committee; NIDA Genetics Workgroup, chair; NIDA Neuroscience Consortium; NIDA Genetics Consortium, chair; Center for Inherited Disease Research (CIDR), board member.

Christine Colvis, Ph.D.
Program Director
(301) 435-1323

Dr. Colvis oversees grants and activities focused on the biochemistry and molecular cell biology of drug abuse, neuroscience and co-morbid conditions such as HIV and hepatitis C. Dr. Colvis also directs the proteomics program at NIDA and is actively involved in promoting NIDAs Cutting Edge Basic Research Award (CEBRA) program.

Activities: NIH Proteomics Interest Group (ProtIG) and steering committee member; Trans-NIH Extramural Proteomics Committee; co-chair of the Baltimore-Washington Mass Spectrometry Discussion Group; NIH Committee on Scientific Conduct and Ethics ex officio member; NIDA Neuroscience Consortium member; NIDA Genetics Workgroup member; Emerging Technologies Workgroup member.

John Satterlee, Ph.D.
Health Scientist Administrator
(301) 435-1020

Dr. Satterlee oversees grants and activities focused on the genetics of drug abuse. One area of interest is the utilization of molecular and genetic resources in model organisms such as C. elegans, Drosophila, zebrafish, mouse, and others to answer fundamental questions in drug abuse biology and behavioral plasticity. Another area of interest is the role of signal transduction cascades in the regulation of neuronal gene expression and function. Of particular interest is the role of G-protein signaling in these processes.

A third area of interest is in the development of robust genetic tools to treat drug addiction. RNA interference and gene therapy strategies have potential value in drug addiction pharmacotherapy. Pharmaceutical development for any specific disease is a major undertaking since it is expensive and time consuming to develop a new small molecule to inhibit each distinct disease gene. Genetic technologies may yield a rapid and generally applicable method to downregulate any specific gene, allele, or splice form involved in a particular human disease such as drug addiction.

Activities: NIDA Genetics Workgroup, NIDA Neuroscience Consortium, NIH Knockout Mouse Project, Trans-NIH Zebrafish Committee, Trans-NIH Genomic Resources Committee.

Da-Yu Wu, Ph.D.
Health Scientist Administrator
(301) 435-4649
wudy@nida.nih.gov

Dr. Wu's programmatic interest is developmental neurobiology. He oversees efforts on the research in the development and plasticity of the reward and motivation pathways with particular emphasis on prenatal and adolescent period of exposure to drugs of abuse, focusing on synapse growth and modulation, axonal pathfinding and neural circuitry establishment. He also has strong interests in neuronal/glial cell fate, differentiation and stem cell biology. His portfolio in addition includes areas of cell and molecular imaging, animal modeling of drug abuse, and RNA regulation during neural development.

Activities: Member of the Trans-NIH Stem Cell Committee, NIDA AIDS Workgroup, and NIDA Genetics Workgroup.

Mark Caulder, M.S., M.P.H.
Health Program Specialist for Population and Applied Genetics
(301) 443-1887


Recent Initiatives

Microarray-Based Research on Drug Abuse
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-00-003.html
Thirteen grants were funded in 2000 through this one-time initiative. Since this initiative committed the grantees to data sharing, the Principal Investigators meet annually to discuss ways that will facilitate sharing of the large data sets generated.

Mutagenesis Screens/Phenotyping Tools for Zebrafish
http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-00-004.html
NIDA joined this trans-NIH initiative aimed at exploiting the power of mutagenesis screening in zebrafish in order to detect and characterize genes, pathways, and phenotypes of interest in development, behavior, organ formation, disease processes.

Gene Expression Profiling in the Nervous System
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-00-002.html
NIDA co-sponsored this NIMH initiative to support research on microarray-based gene expression profiling and funded two grants.

Developmental Pharmacology
http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-00-001.html
NIDA co-sponsored this NICHD initiative that solicited proposals to study the ontogeny of drug metabolizing enzymes, transporters, and receptors, and the corresponding ion channels and related proteins, and funded three grants.

Links to Genetics Workgroup Homepage and Genetics Resources
http://www.nida.nih.gov/genetics/geneticshome.html


About NIDA Contents




NIDA Home | Site Map | Search | FAQs | Accessibility | Help | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Tuesday, May 6, 2008. The U.S. government's official web portal